GI CANCERS

A new study reveals serplulimab significantly improves event-free survival in gastric cancer, offering a promising alternative to traditional chemotherapy.

Discover the most anticipated abstracts on gastrointestinal cancers at the 2025 ESMO Congress, featuring groundbreaking studies and innovative treatments.

The FDA fast-tracks NG-350A, an innovative immunotherapy for advanced rectal cancer, aiming to enhance treatment options and patient outcomes.

New dosimetry data highlights the safety and efficacy of ITM-11 for treating patients with gastroenteropancreatic neuroendocrine tumors, promising improved outcomes.

A phase 2 trial reveals that ONO-4578 and nivolumab significantly extend progression-free survival in advanced gastric cancer patients.

Atebimetinib combined with modified gemcitabine/nab-paclitaxel shows remarkable survival rates in first-line pancreatic cancer, surpassing standard treatments.

Discover the most anticipated late-breaking abstracts in gastrointestinal cancers at ESMO 2025 and influence the conversation in oncology research.

Mitazalimab shows promising efficacy and safety in metastatic pancreatic cancer, paving the way for a pivotal phase 3 trial.

A novel combination therapy shows promising results in metastatic colorectal cancer, offering improved response rates and survival compared to existing treatments.

Jason S. Starr, DO, discusses the CABINET trial of cabozantinib in pancreatic neuroendocrine tumors.

A groundbreaking clinical trial explores botensilimab/balstilimab combination therapy, offering new hope for advanced colorectal cancer patients lacking effective immunotherapy options.

Guardant Health's Shield test shows promising results in colorectal cancer screening, enhancing early detection and patient access with a noninvasive blood test.

During a live event, Kashif Ali, MD, discussed outcomes from the NAPOLI 3 trial in terms of efficacy, tolerability, and dose modification.

A new triple therapy shows promising results for treating BRAF V600E-mutant metastatic colorectal cancer, significantly improving patient outcomes.

Zymeworks discontinues ZW171 clinical development after phase 1 trial reveals unfavorable benefit-risk profile, shifting focus to other promising candidates.

The FDA has granted breakthrough device designation to the Haystack MRD test, a circulating tumor DNA (ctDNA) test, for use in patients with stage II colorectal cancer following surgery.

The FDA approves Agilent's MMR IHC Panel, enhancing personalized colorectal cancer treatment by identifying patients for targeted immunotherapy options.

During a live event, Kashif Ali, MD, reviewed the efficacy and safety of the NAPOLI 1 trial in patients with pancreatic cancer.

Mabwell's 7MW4911 receives FDA IND clearance, paving the way for clinical trials targeting advanced GI cancers with promising preclinical results.

Zev A. Wainberg, MD, discussed the significance of the AMPLIFY-201 trial, next steps for this vaccine platform, and the signs of progress he has recently seen in this challenging disease setting.

Zev A. Wainberg, MD, discussed the significance of the immune response signals in a phase 1 trial of an amphiphile vaccine for pancreatic cancer.

New findings reveal promising efficacy of irpagratinib and atezolizumab in treating advanced hepatocellular carcinoma with FGF19 overexpression.

Trifluridine/tipiracil shows potential in improving disease-free survival in colorectal cancer patients post-surgery, despite safety concerns.

Atezolizumab and bevacizumab enhance TACE effectiveness, significantly extending progression-free survival in unresectable HCC patients, as shown in the TALENTACE trial.

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal cancer, particularly if they had strong T-cell responses.